HC Wainwright restated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $32.00 price target on the biotechnology company’s stock. IOVA has been the topic of a number of other research reports. Barclays raised their price target on […]
HC Wainwright reiterated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research report sent to investors on Friday, Benzinga reports. HC Wainwright currently has a $32.00 price target on the biotechnology company’s stock. A number of other research analysts have also weighed in on IOVA. The Goldman Sachs Group […]
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Pier 88 Investment Partners LLC bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 27,290 shares of the biotechnology company’s stock, valued at approximately $222,000. A […]
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued a report […]